Does ALT tell me anything about hepatic fat on mazdutide?

Stated plainly: ALT · mazdutide.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

What is the causal chain, and where does it stop being established?

The relevant caution is that a rapid rise, particularly with bilirubin, is a different event from a stable mild elevation and needs handling differently.

Alanine aminotransferase is relatively liver-specific; aspartate aminotransferase is also present in muscle, heart and red cells. A raised AST with a normal ALT after heavy resistance training is usually muscle, and creatine kinase settles the question.

More usefully, creatine kinase, alkaline phosphatase and bilirubin together tell you which compartment the abnormality is in, and ordering the transaminases alone throws that information away.

Population data show a substantial fraction of adults with mild transaminase elevation attributable to hepatic steatosis, which sets the base rate against which any new finding should be read.

The caveat is direct: rising liver enzymes with jaundice, dark urine or right-upper-quadrant pain is a same-day clinical problem, not a forum question.

Transaminases plus bilirubin plus alkaline phosphatase, or you have not measured enough to conclude anything.

Before attributing anything to a compound, account for alcohol, muscle injury from new training, and any over-the-counter product being taken alongside.

Weight loss of ten per cent or more typically reduces transaminases substantially in people whose elevation was driven by hepatic fat, which is the majority of mild elevations in this population.

Very rapid weight loss can transiently worsen liver biochemistry, which is one of several arguments against pursuing the steepest possible trajectory.

Nothing here is medical advice. An abnormal result needs somebody who can take a history and examine you.

New training, alcohol and over-the-counter products first. Then the interesting hypotheses.

edited 3 Aug 2025 by zainab_mustafa — removed a claim I could not source

Answer first: mild transaminase elevation is common in this population before any drug is involved, and the usual cause is hepatic steatosis rather than anything acute.

An isolated result three weeks after starting anything is difficult to interpret. A baseline taken before starting makes the same result trivially interpretable, which is the argument for baselines.

Laboratory-specific reference intervals for transaminases vary enough that cross-laboratory comparison of borderline values is unreliable.

Attributing an enzyme change to a compound requires a baseline, and most people asking have not got one.

Get a baseline before you start anything, because it converts an uninterpretable result into an interpretable one for the cost of one blood draw.

The short version: enzymes in this class usually fall as weight falls, and a rise is a reason to look for a cause rather than to assume a drug effect.

Reference upper limits around forty units per litre for ALT are conventional rather than physiological; several groups have argued for limits closer to thirty for men and twenty-five for women.

Hy's law and its variants are the standard framework for identifying drug-induced liver injury in trials and are why bilirubin is measured alongside transaminases rather than instead.

The caveat is the population. Trial participants were screened, monitored and supported; the effect size in an unmonitored setting is not the trial effect size, and it is not obvious in which direction the difference runs.

Isolated mild elevation is common and usually improves with weight loss.